ATLANTA, July 16, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. (Tikvah) and Chicago-based Apkarian Technologies, LLC (Apkarian) announced today that Tikvah has entered into an exclusive licensing agreement with Apkarian for patents and patent applications involving certain agonists of specific sites of the NMDA receptor.
